P53355

※ Protein Information

Tag	Content
UniProt Accession	DAPK1_HUMAN; P53355;
Entrez ID	1612
GenBank Protein ID	NM_001288729.1; NM_001288730.1; NM_001288731.1; NM_004938.3;
GenBank Nucleotide ID	NP_001275658.1; NP_001275659.1; NP_001275660.1; NP_004929.2;
Protein Name	Death-associated protein kinase 1 (DAP kinase 1) (EC 2.7.11.1)
Gene Name	DAPK1; DAPK
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Calcium/calmodulin-dependent serine/threonine kinase involved in multiple cellular signaling pathways that trigger cell survival, apoptosis, and autophagy. Regulates both type I apoptotic and type II autophagic cell deaths signal, depending on the cellular setting. The former is caspase-dependent, while the latter is caspase-independent and is characterized by the accumulation of autophagic vesicles. Phosphorylates PIN1 resulting in inhibition of its catalytic activity, nuclear localization, and cellular function. Phosphorylates TPM1, enhancing(view all) Functional Description Calcium/calmodulin-dependent serine/threonine kinase involved in multiple cellular signaling pathways that trigger cell survival, apoptosis, and autophagy. Regulates both type I apoptotic and type II autophagic cell deaths signal, depending on the cellular setting. The former is caspase-dependent, while the latter is caspase-independent and is characterized by the accumulation of autophagic vesicles. Phosphorylates PIN1 resulting in inhibition of its catalytic activity, nuclear localization, and cellular function. Phosphorylates TPM1, enhancing stress fiber formation in endothelial cells. Phosphorylates STX1A and significantly decreases its binding to STXBP1. Phosphorylates PRKD1 and regulates JNK signaling by binding and activating PRKD1 under oxidative stress. Phosphorylates BECN1, reducing its interaction with BCL2 and BCL2L1 and promoting the induction of autophagy. Phosphorylates TSC2, disrupting the TSC1-TSC2 complex and stimulating mTORC1 activity in a growth factor-dependent pathway. Phosphorylates RPS6, MYL9 and DAPK3. Acts as a signaling amplifier of NMDA receptors at extrasynaptic sites for mediating brain damage in stroke. Cerebral ischemia recruits DAPK1 into the NMDA receptor complex and it phosphorylates GRINB at Ser-1303 inducing injurious Ca(2+) influx through NMDA receptor channels, resulting in an irreversible neuronal death. Required together with DAPK3 for phosphorylation of RPL13A upon interferon-gamma activation which is causing RPL13A involvement in transcript-selective translation inhibition.;Isoform 2 cannot induce apoptosis but can induce membrane blebbing.
Sequence (Fasta)	MTVFRQENVD DYYDTGEELG SGQFAVVKKC REKSTGLQYA AKFIKKRRTK SSRRGVSRED 60 IEREVSILKE IQHPNVITLH EVYENKTDVI LILELVAGGE LFDFLAEKES LTEEEATEFL 120 KQILNGVYYL HSLQIAHFDL KPENIMLLDR NVPKPRIKII DFGLAHKIDF GNEFKNIFGT 180 PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGD TKQETLANVS AVNYEFEDEY 240 FSNTSALAKD FIRRLLVKDP KKRMTIQDSL QHPWIKPKDT QQALSRKASA VNMEKFKKFA 300 ARKKWKQSVR LISLCQRLSR SFLSRSNMSV ARSDDTLDEE DSFVMKAIIH AINDDNVPGL 360 QHLLGSLSNY DVNQPNKHGT PPLLIAAGCG NIQILQLLIK RGSRIDVQDK GGSNAVYWAA 420 RHGHVDTLKF LSENKCPLDV KDKSGEMALH VAARYGHADV AQLLCSFGSN PNIQDKEEET 480 PLHCAAWHGY YSVAKALCEA GCNVNIKNRE GETPLLTASA RGYHDIVECL AEHGADLNAC 540 DKDGHIALHL AVRRCQMEVI KTLLSQGCFV DYQDRHGNTP LHVACKDGNM PIVVALCEAN 600 CNLDISNKYG RTPLHLAANN GILDVVRYLC LMGASVEALT TDGKTAEDLA RSEQHEHVAG 660 LLARLRKDTH RGLFIQQLRP TQNLQPRIKL KLFGHSGSGK TTLVESLKCG LLRSFFRRRR 720 PRLSSTNSSR FPPSPLASKP TVSVSINNLY PGCENVSVRS RSMMFEPGLT KGMLEVFVAP 780 THHPHCSADD QSTKAIDIQN AYLNGVGDFS VWEFSGNPVY FCCYDYFAAN DPTSIHVVVF 840 SLEEPYEIQL NQVIFWLSFL KSLVPVEEPI AFGGKLKNPL QVVLVATHAD IMNVPRPAGG 900 EFGYDKDTSL LKEIRNRFGN DLHISNKLFV LDAGASGSKD MKVLRNHLQE IRSQIVSVCP 960 PMTHLCEKII STLPSWRKLN GPNQLMSLQQ FVYDVQDQLN PLASEEDLRR IAQQLHSTGE 1020 INIMQSETVQ DVLLLDPRWL CTNVLGKLLS VETPRALHHY RGRYTVEDIQ RLVPDSDVEE 1080 LLQILDAMDI CARDLSSGTM VDVPALIKTD NLHRSWADEE DEVMVYGGVR IVPVEHLTPF 1140 PCGIFHKVQV NLCRWIHQQS TEGDADIRLW VNGCKLANRG AELLVLLVNH GQGIEVQVRG 1200 LETEKIKCCL LLDSVCSTIE NVMATTLPGL LTVKHYLSPQ QLREHHEPVM IYQPRDFFRA 1260 QTLKETSLTN TMGGYKESFS SIMCFGCHDV YSQASLGMDI HASDLNLLTR RKLSRLLDPP 1320 DPLGKDWCLL AMNLGLPDLV AKYNTSNGAP KDFLPSPLHA LLREWTTYPE STVGTLMSKL 1380 RELGRRDAAD FLLKASSVFK INLDGNGQEA YASSCNSGTS YNSISSVVSR 1431 Fasta Sequence >P53355\|DAPK1; DAPK\|Homo sapiens (Human) MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSRKASAVNMEKFKKFAARKKWKQSVRLISLCQRLSRSFLSRSNMSVARSDDTLDEEDSFVMKAIIHAINDDNVPGLQHLLGSLSNYDVNQPNKHGTPPLLIAAGCGNIQILQLLIKRGSRIDVQDKGGSNAVYWAARHGHVDTLKFLSENKCPLDVKDKSGEMALHVAARYGHADVAQLLCSFGSNPNIQDKEEETPLHCAAWHGYYSVAKALCEAGCNVNIKNREGETPLLTASARGYHDIVECLAEHGADLNACDKDGHIALHLAVRRCQMEVIKTLLSQGCFVDYQDRHGNTPLHVACKDGNMPIVVALCEANCNLDISNKYGRTPLHLAANNGILDVVRYLCLMGASVEALTTDGKTAEDLARSEQHEHVAGLLARLRKDTHRGLFIQQLRPTQNLQPRIKLKLFGHSGSGKTTLVESLKCGLLRSFFRRRRPRLSSTNSSRFPPSPLASKPTVSVSINNLYPGCENVSVRSRSMMFEPGLTKGMLEVFVAPTHHPHCSADDQSTKAIDIQNAYLNGVGDFSVWEFSGNPVYFCCYDYFAANDPTSIHVVVFSLEEPYEIQLNQVIFWLSFLKSLVPVEEPIAFGGKLKNPLQVVLVATHADIMNVPRPAGGEFGYDKDTSLLKEIRNRFGNDLHISNKLFVLDAGASGSKDMKVLRNHLQEIRSQIVSVCPPMTHLCEKIISTLPSWRKLNGPNQLMSLQQFVYDVQDQLNPLASEEDLRRIAQQLHSTGEINIMQSETVQDVLLLDPRWLCTNVLGKLLSVETPRALHHYRGRYTVEDIQRLVPDSDVEELLQILDAMDICARDLSSGTMVDVPALIKTDNLHRSWADEEDEVMVYGGVRIVPVEHLTPFPCGIFHKVQVNLCRWIHQQSTEGDADIRLWVNGCKLANRGAELLVLLVNHGQGIEVQVRGLETEKIKCCLLLDSVCSTIENVMATTLPGLLTVKHYLSPQQLREHHEPVMIYQPRDFFRAQTLKETSLTNTMGGYKESFSSIMCFGCHDVYSQASLGMDIHASDLNLLTRRKLSRLLDPPDPLGKDWCLLAMNLGLPDLVAKYNTSNGAPKDFLPSPLHALLREWTTYPESTVGTLMSKLRELGRRDAADFLLKASSVFKINLDGNGQEAYASSCNSGTSYNSISSVVSR

※ PTM-Disease Association

Num	PTM	Disease	Cell Type	Type	PTM Site	PMID
1	Methylation	Gastric cancer		P		24640104
1	[Reference]: The study was organized to investigate the anomalous methylation of genes NA1, RASSF1A, MLH1, N33, DAPK, the expression of genes Htert These changes can be used as additional markers both in diagnostic of cancer of stomach and dynamic monitoring of operated patients.

※ Disease Cross-ref Annotation

Database	Annotation
CTD (Curated) (count: 16) (view all)	MESH:D000230 ; Adenocarcinoma MESH:D001171 ; Arthritis, Juvenile MESH:D001932 ; Brain Neoplasms MESH:D003528 ; Carcinoma, Adenoid Cystic MESH:D002292 ; Carcinoma, Renal Cell MESH:D002295 ; Carcinoma, Transitional Cell MESH:D003229 ; Conjunctival Diseases MESH:D015470 ; Leukemia, Myeloid, Acute MESH:D008175 ; Lung Neoplasms MESH:D009190 ; Myelodysplastic Syndromes MESH:D009362 ; Neoplasm Metastasis MESH:D016609 ; Neoplasms, Second Primary MESH:D002289 ; Carcinoma, Non-Small-Cell Lung MESH:D010523 ; Peripheral Nervous System Diseases MESH:D012140 ; Respiratory Tract Diseases MESH:D012468 ; Salivary Gland Neoplasms
DisGeNet (Curated) (count: 16) (view all)	C0001418; Adenocarcinoma C0006118; Brain Neoplasms C0007131; Non-Small Cell Lung Carcinoma C0007134; Renal Cell Carcinoma C0007138; Carcinoma, Transitional Cell C0009759; Conjunctival Diseases C0010606; Adenoid Cystic Carcinoma C0023467; Leukemia, Myelocytic, Acute C0024121; Lung Neoplasms C0027627; Neoplasm Metastasis C0031117; Peripheral Neuropathy C0035242; Respiratory Tract Diseases C0036095; Salivary Gland Neoplasms C0085183; Neoplasms, Second Primary C3463824; MYELODYSPLASTIC SYNDROME C3495559; Juvenile arthritis
HGMD (count: 3)	CM071685; Inactivation of ERK-induced apoptosis, association; Missense/nonsense CS064394; Alzheimer disease, late onset, association with; Splicing CS064395; Alzheimer disease, late onset, association with; Splicing
GWASdb (count: 43) (view all)	rs868477; Multiple complex diseases; Null rs7849249; Type 2 diabetes; type 2 diabetes mellitus rs12378187; Type 2 diabetes; type 2 diabetes mellitus rs11141869; Type 2 diabetes; type 2 diabetes mellitus rs4878097; Type 2 diabetes; type 2 diabetes mellitus rs4877364; Type 2 diabetes; type 2 diabetes mellitus rs4877365; Type 2 diabetes; type 2 diabetes mellitus rs1421001; Cognitive function; cognitive disorder rs1421001; Calcium levels; calcium metabolism disease\|atherosclerosis rs10780856; Type 2 diabetes; type 2 diabetes mellitus rs1157645; Cognitive function; cognitive disorder rs2026742; Type 2 diabetes; type 2 diabetes mellitus rs11141876; Multiple complex diseases; Null rs11141876; Blood pressure (response to angiotensin-converting enzyme inhibitor); hypertension rs1045211; Multiple complex diseases; Null rs6560001; Insulin resistance; type 2 diabetes mellitus rs10868625; Type 2 diabetes; type 2 diabetes mellitus rs11141883; Type 2 diabetes; type 2 diabetes mellitus rs7855623; Type 2 diabetes; type 2 diabetes mellitus rs7855635; Type 2 diabetes; type 2 diabetes mellitus rs7869390; Type 2 diabetes; type 2 diabetes mellitus rs17479142; Type 2 diabetes; type 2 diabetes mellitus rs17479142; Personality dimensions; personality disorder rs17479184; Type 2 diabetes; type 2 diabetes mellitus rs17479184; Personality dimensions; personality disorder rs4878102; Type 2 diabetes; type 2 diabetes mellitus rs1861832; Type 2 diabetes; type 2 diabetes mellitus rs6560005; Serum metabolites; Null rs6560005; Cognitive function; cognitive disorder rs928114; Type 2 diabetes; type 2 diabetes mellitus rs928114; Personality dimensions; personality disorder rs11141896; Type 2 diabetes; type 2 diabetes mellitus rs12685116; Type 2 diabetes; type 2 diabetes mellitus rs7031264; Type 2 diabetes; type 2 diabetes mellitus rs12685372; Type 2 diabetes; type 2 diabetes mellitus rs3095748; Immune reponse to smallpox (secreted IFN-alpha); smallpox rs7869944; Lung function (forced expiratory volume in 1 second to forced vital capacity ratio); lung disease rs11141915; Response to gemcitabine in pancreatic cancer; pancreatic cancer rs3118867; Blood pressure; hypertension rs943855; Cognitive impairment induced by topiramate; cognitive disorder rs721936; Multiple complex diseases; Null rs10868644; Bipolar disorder; bipolar disorder rs13283425; Type 2 diabetes; type 2 diabetes mellitus

※ PTM Sites

PTM	Modification Sites
Phosphorylation (count: 22) (view all)	1060 TPRALHHYRGRYTVE dbPAF 12 RQENVDDYYDTGEEL dbPAF 1266 RAQTLKETSLTNTMG dbPAF 1267 AQTLKETSLTNTMGG dbPAF 1269 TLKETSLTNTMGGYK dbPAF 13 QENVDDYYDTGEELG dbPAF 289 QALSRKASAVNMEKF dbPAF 308 ARKKWKQSVRLISLC dbPAF 319 ISLCQRLSRSFLSRS dbPAF 324 RLSRSFLSRSNMSVA dbPAF 326 SRSFLSRSNMSVARS dbPAF 333 SNMSVARSDDTLDEE dbPAF 39 EKSTGLQYAAKFIKK dbPAF 490 HCAAWHGYYSVAKAL dbPAF 491 CAAWHGYYSVAKALC dbPAF 57 KSSRRGVSREDIERE dbPAF 606 ANCNLDISNKYGRTP dbPAF 696 KLKLFGHSGSGKTTL dbPAF 724 RRRRPRLSSTNSSRF dbPAF 725 RRRPRLSSTNSSRFP dbPAF 728 PRLSSTNSSRFPPSP dbPAF 734 NSSRFPPSPLASKPT dbPAF
Ubiquitination (count: 2)	306 FAARKKWKQSVRLIS PLMD 939 DAGASGSKDMKVLRN PLMD

PTM

Modification Sites

Phosphorylation
(count: 22)
(view all)

1060      TPRALHHYRGRYTVE     dbPAF
12        RQENVDDYYDTGEEL     dbPAF
1266      RAQTLKETSLTNTMG     dbPAF
1267      AQTLKETSLTNTMGG     dbPAF
1269      TLKETSLTNTMGGYK     dbPAF
13        QENVDDYYDTGEELG     dbPAF

Ubiquitination
(count: 2)

306 FAARKKWKQSVRLIS PLMD
939 DAGASGSKDMKVLRN PLMD

※ Protein-Protein Interaction

Network

Interaction

Source

P27361	P53355	HPRD; IntAct
P28482	P53355	HPRD
P53355	Q14457	MINT
P53355	Q92905	IntAct

PTMD Annotation Information

※ Protein Information

Functional Description

Fasta Sequence

※ PTM-Disease Association

※ Disease Cross-ref Annotation

※ PTM Sites

※ Protein-Protein Interaction